Wei Wei - Publications

Affiliations: 
Stanford University, Palo Alto, CA 
Area:
Molecular Neuroscience

30 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Heo K, Basu H, Gutnick A, Wei W, Shlevkov E, Schwarz TL. Serine/Threonine Protein Phosphatase 2A Regulates the Transport of Axonal Mitochondria. Frontiers in Cellular Neuroscience. 16: 852245. PMID 35370563 DOI: 10.3389/fncel.2022.852245  0.34
2021 Basu H, Pekkurnaz G, Falk J, Wei W, Chin M, Steen J, Schwarz TL. FHL2 anchors mitochondria to actin and adapts mitochondrial dynamics to glucose supply. The Journal of Cell Biology. 220. PMID 34342639 DOI: 10.1083/jcb.201912077  0.315
2019 Shlevkov E, Basu H, Bray MA, Sun Z, Wei W, Apaydin K, Karhohs K, Chen PF, Smith JLM, Wiskow O, Roet K, Huang X, Eggan K, Carpenter AE, Kleiman RJ, et al. A High-Content Screen Identifies TPP1 and Aurora B as Regulators of Axonal Mitochondrial Transport. Cell Reports. 28: 3224-3237.e5. PMID 31533043 DOI: 10.1016/J.Celrep.2019.08.035  0.397
2017 Qi R, Wang Y, Bruno PM, Xiao H, Yingjie Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, et al. Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nature Communications. 8: 2166. PMID 29255160 DOI: 10.1038/S41467-017-02390-7  0.34
2017 Wei W, Giulia F, Luffer S, Kumar R, Wu B, Tavallai M, Bekele RT, Birrer MJ. How can molecular abnormalities influence our clinical approach. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: viii16-viii24. PMID 29232470 DOI: 10.1093/Annonc/Mdx447  0.326
2017 Tsang TY, Wei W, Itamochi H, Tambouret R, Birrer MJ. Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic target. Oncotarget. 8: 96482-96495. PMID 29228547 DOI: 10.18632/Oncotarget.19946  0.371
2017 Yi Y, Tsai SH, Cheng JC, Wang EY, Anglesio MS, Cochrane DR, Fuller M, Gibb EA, Wei W, Huntsman DG, Karsan A, Hoodless PA. APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner. Gynecologic Oncology. PMID 29079036 DOI: 10.1016/J.Ygyno.2017.10.016  0.306
2017 Cheng R, Liu YJ, Cui JW, Yang M, Liu XL, Li P, Wang Z, Zhu LZ, Lu SY, Zou L, Wu XQ, Li YX, Zhou Y, Fang ZY, Wei W. Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells. Oncotarget. PMID 28415819 DOI: 10.18632/Oncotarget.16325  0.302
2017 Cheng R, Cui J, Fang Z, Liu X, Wei W. Expression of HOX transcription antisense RNA in triple-negative breast cancer and its clinical significance Chinese Journal of Experimental Surgery. 34: 1391-1393. DOI: 10.3760/Cma.J.Issn.1001-9030.2017.08.041  0.311
2017 Kumar R, Wei W, Lauffer S, Fulci G, Birrer MJ. Harnessing IMGN853-mediated cell cytoxicity response by modulating FRα expression in ovarian cancer. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E17061  0.329
2017 Wei W, Birrer MJ. Abstract TMEM-040: TUMOR ASSOCIATED MACROPHAGES MEDIATES THE ONCOGENIC EFFECT OF FGF18 IN OVARIAN CANCER Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Ovcasymp16-Tmem-040  0.352
2017 Wei W, Birrer MJ. Abstract NTOC-113: TGF–β SIGNALING INHIBITION AS A POTENTIAL APPROACH TO TARGET SUBOPTIMALLY DEBULKED OVARIAN TUMORS Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Ovcasymp16-Ntoc-113  0.36
2017 Chi R, Wei W, Birrer M, Leaner VD. Abstract 1069: Inhibition of the nuclear import receptor, KpnB1 synergizes with cisplatin toxicity in cervical cancer cells Cancer Research. 77: 1069-1069. DOI: 10.1158/1538-7445.Am2017-1069  0.363
2016 Ai R, Sun Y, Guo Z, Wei W, Zhou L, Liu F, Hendricks DT, Xu Y, Zhao X. NDRG1 overexpression promotes the progression of esophageal squamous cell carcinoma through modulating Wnt signaling pathway. Cancer Biology & Therapy. 0. PMID 27414086 DOI: 10.1080/15384047.2016.1210734  0.339
2016 van der Watt PJ, Chi A, Stelma T, Stowell C, Strydom E, Carden S, Angus L, Hadley K, Lang D, Wei W, Birrer MJ, Trent JO, Leaner VD. Targeting the nuclear import receptor, Kpnβ1 as an anti-cancer therapeutic. Molecular Cancer Therapeutics. PMID 26832790 DOI: 10.1158/1535-7163.Mct-15-0052  0.365
2016 Wei W, Birrer M. Abstract 4083: Tumor associated macrophages mediates the oncogenic effect of FGF18 in ovarian cancer Cancer Research. 76: 4083-4083. DOI: 10.1158/1538-7445.Am2016-4083  0.348
2015 Wei W, Birrer MJ. Spleen Tyrosine Kinase Confers Paclitaxel Resistance in Ovarian Cancer. Cancer Cell. 28: 7-9. PMID 26175410 DOI: 10.1016/J.Ccell.2015.06.008  0.325
2015 Vathipadiekal V, Wang V, Wei W, Waldron L, Drapkin R, Gillette M, Skates S, Birrer M. Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 4960-9. PMID 25944803 DOI: 10.1158/1078-0432.Ccr-14-3173  0.34
2015 Wei W, Brady MF, Tsang T, Vathipadiekal V, Burger RA, Mannel RS, Hanjani P, Huh WK, Swisher EM, Rutherford TJ, Tanyi JL, Schink JC, Lele SB, DiSilvestro PA, Birrer MJ. Abstract PR05: An assessment of the prognostic and predictive associations of 13 angiogenic biomarkers in women with newly diagnosed advanced ovarian cancer treated with chemotherapy with or without bevacizumab Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Tumang15-Pr05  0.342
2015 Wei W, Birrer MJ. Abstract 5401: TGF-β signaling inhibition as a potential approach to target suboptimally debulked ovarian tumors Cancer Research. 75: 5401-5401. DOI: 10.1158/1538-7445.Am2015-5401  0.347
2015 Birrer MJ, Wei W, Ceppi L, Tsang TY. The genomic of epithelial ovarian cancer: the past, present, and future Annals of Oncology. 26: vii27. DOI: 10.1093/Annonc/Mdv421.01  0.302
2014 Riester M, Wei W, Waldron L, Culhane AC, Trippa L, Oliva E, Kim SH, Michor F, Huttenhower C, Parmigiani G, Birrer MJ. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. Journal of the National Cancer Institute. 106. PMID 24700803 DOI: 10.1093/Jnci/Dju048  0.311
2014 Birrer MJ, Riester M, Wei W, Waldron L, Culhane A, Trippa L, Oliva E, Kim S, Michor F, Huttenhower C, Parmigiani G. Meta-analysis of public microarray databases for prognostic and predictive gene signatures of late-stage ovarian cancer. Journal of Clinical Oncology. 32: 5531-5531. DOI: 10.1200/Jco.2014.32.15_Suppl.5531  0.32
2014 Riester M, Wei W, Culhane AC, Trippa L, Michor F, Huttenhower C, Parmigiani G, Birrer M. Abstract 2355: Risk prediction for late-stage ovarian cancer by meta-analysis of 1,525 patient samples Cancer Research. 74: 2355-2355. DOI: 10.1158/1538-7445.Am2014-2355  0.337
2013 Wei W, Dizon D, Vathipadiekal V, Birrer MJ. Ovarian cancer: genomic analysis. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: x7-15. PMID 24265410 DOI: 10.1093/Annonc/Mdt462  0.341
2013 Wei W, Mok SC, Oliva E, Kim SH, Mohapatra G, Birrer MJ. FGF18 as a prognostic and therapeutic biomarker in ovarian cancer Journal of Clinical Investigation. 123: 4435-4448. PMID 24018557 DOI: 10.1172/Jci70625  0.368
2013 Wei W, Bracher-Manecke JC, Zhao X, Davies NH, Zhou L, Ai R, Oliver L, Vallette F, Hendricks DT. Oncogenic but non-essential role of N-myc downstream regulated gene 1 in the progression of esophageal squamous cell carcinoma. Cancer Biology & Therapy. 14: 164-74. PMID 23192272 DOI: 10.4161/Cbt.22956  0.301
2013 Na Y, Vathipadiekal V, Wei W, Kwok T, Birrer M. Abstract 3013: Elucidating the functional role of microfibril-associated glycoprotein-2 (MAGP-2) in human ovarian cancer. Cancer Research. 73: 3013-3013. DOI: 10.1158/1538-7445.Am2013-3013  0.377
2013 Kim S, Mok SC, Wei W, Vinod V, Mohapatra G, Birrer M. Abstract 3001: Aberrantly up-regulated synaptotagmin-like 2 (SYTL2) promotes tumorigenesis of ovarian cancer cells . Cancer Research. 73: 3001-3001. DOI: 10.1158/1538-7445.Am2013-3001  0.371
2012 Wei W, Mohapatra G, Birrer MJ. Abstract 1072: The FGF18/FGFR4 amplicon: Novel therapeutic biomarkers for ovarian cancer Cancer Research. 72: 1072-1072. DOI: 10.1158/1538-7445.Am2012-1072  0.376
Show low-probability matches.